1. Home
  2. Browse
  3. National Institutes of Health
  4. RFA-HL-26-016

RFA-HL-26-016National Institutes of HealthR33

Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

Deadline
Award ceiling
$350,000
Awards
Not stated
Posted
Nov 22, 2024

Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.

Or read the full text and all 3 review criteria here, free with an account. Create free account

Summary

This Notice of Funding Opportunity (NOFO) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases…

Related NIH announcements3

Other open R33 announcements on related subjects, with at least two weeks to go.

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)

PAR-25-025National Institutes of Health3 review criteria on file

$1.5M

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

RFA-HL-26-018National Institutes of Health4 review criteria on file

—

Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)

RFA-HL-26-020National Institutes of Health4 review criteria on file

—

The full announcement, free with an account

  • The full announcement text, not just the first two sentences
  • All 3 review criteria reviewers score this against, extracted from this announcement

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
  • Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
  • A Reviewer Scorecard of your draft against these criteria
Create free accountSign in

No card required. Browsing is free.

Subjects

More from National Institutes of Health

Open now with at least two weeks to apply, soonest deadline first.

NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-057National Institutes of Health6 review criteria on file

—

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

RFA-DK-27-108National Institutes of Health3 review criteria on fileagency framework

$500k

Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

RFA-DK-27-139National Institutes of Health

—

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

RFA-DK-27-112National Institutes of Health

—

Everything open from National Institutes of Health

Related by subject

Open opportunities sharing the most subjects with this one (Cardiovascular, Respiratory), with at least two weeks to apply.

NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

PAR-25-032National Institutes of Health3 review criteria on fileagency framework

—

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

PAR-25-026National Institutes of Health3 review criteria on file

—

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)

PAR-25-447National Institutes of Health6 review criteria on file

—

Everything open tagged Cardiovascular

Source record: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-016.htmlVia the NIH Guide. Last checked against the source . Always confirm dates with the funder.